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A Parable
A 40-year-old woman was admitted at midnight to
HMO General Hospital for evaluation of profound
fatigue. Her hemoglobin was found to be 2 g/dL. Her
medical history included several pregnancies and
transfusions. The intern had attended a lecture on
transfusion medicine that day. He ordered a “six-pack,”
six units of random-donor RBCs. The technologist on
call for the blood bank was a bacteriologist, cross-
covering the transfusion service. The technologist
removed six units of RBCs from the refrigerator,pooled
them, and sent a liter of the mixture to the floor for
transfusion, which was quickly followed by back pain
and black urine for the patient.
The intern called the on-call transfusion service
medical director, who was cross-covering from
cardiology. The intern asked, “Can’t you do immuno-
logic testing or provide a matched product?”
The director responded, “No way!
What was the 1-hour CCI? We insist upon two
documented failures before we do an immunology
workup. I’m sending the patient another pool.”
“Oh no, not again!” said the patient. Shortly after
transfusion, back pain and black urine recurred.
The resident called the medical director and said,
“That’s two, Doc!”
“OK.We’ll phenotype the patient’s RBCs and search
for a good BX match in inventory. You know, Jka and Jkb
are crossreactive.”
Once again the patient said, “Are you sure?”
However, the transfusion was given and soon she was
having back pain and black urine again.
In desperation, the medical director said, “I’ll take
random units off the shelf and crossmatch until I find a
compatible unit.” The unit was found and transfused
and there was no back pain or black urine until 5 days
later.
The next day,a new resident,Dr.Peter Petz-Garratty,
came on service. He reviewed the chart and said,“Why
don’t you examine the patient’s serum for antibodies
and determine their antigenic specificities? Then,
crossmatch products without those antigens.”
The medical director said,“This man has a future.”
Evolution of Strategies for RBC Matching
Practice was quite primitive when physicians first
considered transfusing blood from one individual to
another. They began transfusing whole blood between
experimental animals, without any consideration
whatsoever for RBC antigen-antibody compatibility.
Interestingly, this lack of compatibility testing persists
even today for the majority of platelet transfusions.
In an excellent historical review,1 Myhre described
a report by JohnWilkins of a dog-to-dog transfusion of
about 2 ounces of blood via syringe. At that time, it was
not recognized that there was a possibility of naturally
occurring alloantibodies (not present in dogs) or the
relevance of a volume possibly too small to produce a
reaction. Other investigators in London and France
also experimented with animal-to-animal transfusions.
This was done,of course,without compatibility testing.
Since animal-to-animal transfusions went quite well,
soon the time came to try animal-to-human trans-
fusions. Jean Baptiste Denys performed the first animal-
to-human transfusion in mid-1667.2 Nine ounces of
lamb’s blood was transfused to a 16-year-old patient
who had been bled at least 20 times over 2 months.
During the transfusion, it was reported that the patient
experienced “very great heat along his arm.” Again, no
testing of the blood or the recipient was performed.
James Blundell was a major contributor to the early
years of human-to-human blood transfusion. He
reported a transfusion to a patient with obstinate
vomiting, in 1819. The donors were several physicians;
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12 to 24 ounces of blood was given by syringe.2 This is
reminiscent of the use of six packs for platelet
transfusion today. As in the preceding two accounts,no
laboratory testing was carried out on the donor or
recipient blood. These early reports share relatively
small transfused volumes and a lack of pretesting. One
report remarked that animal blood was thought to be
more pure, as the animal did not participate in some of
the risky pursuits that humans did.
Fast forward to today,when involved parties’blood,
both donor and recipient, are subjected to a large
battery of tests. But how did the testing algorithm
develop, and why? As mentioned previously, the first
transfusions were given without testing of the donor or
the recipient. Interest in transfusion waned in the late
19th century due to a high rate of severe adverse
reactions to transfusion.3 Landsteiner’s experiments
and direct transfusions by Carrel, described by Crile,4
promoted a recurrence of interest. The subsequent
determination of ABO groups gave rise to renewed
interest in human-to-human blood transfusion.
In a publication by Ludwig Hektoen,5 what would
become the major and minor crossmatches were
described in 1907. In the early days, the methods
concentrated solely upon detection of room
temperature IgM antibodies, as the “Coombs test” had
not yet been described. Thus, these investigators were
studying ABO compatibility. Ottenberg6 and Epstein7
studied a method for hemolysis and agglutination tests.
Epstein promoted a pretransfusion crossmatch, using
tests both for hemolysis and for agglutination. It was
later recognized that when agglutination was present
hemolysis might also be present, but in vitro hemolysis
did not occur without agglutination.8 With this
information, agglutination tests could be used without
tests for hemolysis. At this time, all testing still
concentrated upon detection of IgM antibodies.
Changes like the recommendation for testing at 37°C
and concentration upon the major crossmatch
followed. DuringWorldWar I,Lee proposed that if type
O blood were used, preliminary testing could be
avoided.9
These red cell innovations in the early part of the
20th century were quite similar to the use of “blind”
crossmatching to assess platelet compatibility today.
The first practical method for platelet crossmatching
was not described until 1988.10 This will be discussed
further in the next portion of this paper.
Major changes to detect IgG antibodies followed
the reports of enhancement of agglutination with
bovine albumin11 and antiglobulin testing.12 Although
other enhancement media and techniques (enzyme,
LISS, PEG, and solid phase and column agglutination
technology) have been described, the basic premise of
the major crossmatch remains remarkably the same, ie.,
with testing of the patient’s serum against donor RBCs.
At first, the minor crossmatch was also felt to be
necessary, but a paradigm shift occurred. The minor
crossmatch was eventually abandoned in favor of
routine donor antibody screening. The need for
complement-reactive antihuman globulin (AHG) sera
has been eliminated because of the rare occurrence of
clinically significant antibodies leaving only comple-
ment on the cell surface. The requirement for serum as
a source of a test sample has been changed for the
same reason.
Another change was the departure from room
temperature testing to 37°C for detection of potentially
significant antibodies. Most clinically significant
antibodies are reactive at 37°C, and antibodies reactive
solely at room temperature are generally not thought to
have clinical significance.
More recently, AABB standards have allowed the
use of immediate spin testing as long as the patient’s
antibody screen is negative. In some laboratories,
electronic crossmatches have taken the place of the
AHG crossmatch. Thus, few patients’ samples are
routinely subjected to an AHG crossmatch. When the
antibody screen is positive, RBC units are selected that
lack antigens to which the antibody is directed. This is
quite similar to the evolution of antibody-based
matching for platelets.
The number of RBC transfusions requiring a full
crossmatch is proportionate to the number of platelet
transfusions currently guided by crossmatch testing,
but for vastly different reasons. In the case of potential
RBC recipients, an AHG crossmatch will be required by
the serologic determination of alloantibodies or
autoantibodies. In the case of potential platelet
recipients, however, crossmatching is ordered after
several transfusions have not yielded expected
increments. The present status of platelet cross-
matching, then, parallels the state of RBC testing in the
early 1900s.
Evaluation of Strategies for Platelet Matching
In current practice,platelet transfusion begins with
randomly selected platelet products, either pooled
whole-blood–derived platelets or platelets prepared by
apheresis. This is analogous to the initial management
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of the anemic woman in the parable. This approach
continues until the patient is refractory, i.e., fails to
show adequate increments after transfusion. To
identify a patient as refractory, most clinicians require
two or three failed transfusions. Again, this was the
way the patient in the parable was managed.
Commonly, increments are expressed as corrected
count increments (CCI) where
CCI = Plt. Ct. Increment (/µL) × Body Surface Area (m2)
Plts.Transfused (× 1011)
Refractoriness is commonly defined as a CCI less
than 4000 per µL per m2 per 1011 platelets.13 Thus,
patients have to “earn” immunologic intervention by
experiencing several therapeutic failures, as the
woman in the parable did. This reactive policy
contrasts with RBC transfusion,where patients are now
screened for antibody before each transfusion, as
suggested by “Dr. Petz-Garratty.”
Most immunologic platelet refractoriness results
from antibodies to HLA. It is important to emphasize
that clinical refractoriness is often due not to alloim-
munization but, rather, to clinical factors such as
infection, splenomegaly, or disseminated intravascular
coagulation.14 Thus, it would make sense to perform
one or more serologic tests to prove that alloimmu-
nization was present. However, this approach was rare
during the first 20 to 25 years of matched-platelet
transfusions.15,16
The classical HLA approach to platelet matching
began with the paper by Yankee et al.15 that compared
the use of platelets from HLA-identical siblings with
randomly selected platelets in refractory patients.
There were no increments with random products but
excellent responses to the perfectly HLA-matched
sibling donors.
It is generally not realistic to support refractory
patients with sibling donors. Duquesnoy et al.16
introduced the concept of supporting patients with
HLA-matched platelets from the general population.
However, they noted that a pool of 50,000 donors
would be required to provide a 50 percent probability
of finding ten perfectly matched donors for each of 100
potential recipients. This was also unrealistic. They
proposed a method that we will call the CREG method.
Cross-reactive groups (CREGs) of HLA antigens have
been defined by serologic testing. Cross-reactivity
among antigens within a CREG results from the sharing
of one or more public epitopes. Patients do not make
antibody to their own HLA antigens nor commonly to
antigens within CREGs of their own HLA antigens.16
Therefore,Duquesnoy et al.16 defined matches between
donor and patient as A, HLA identical; BU, (partially
homozygous) donor antigens all present in the
recipient; BX, all donor HLA antigens either identical to
or within recipient CREGs; C & D, one or more donor
antigens not present in recipient or in recipient CREGs.
This is analogous to the phenotypic matching of RBCs.
The use of BX matches greatly expanded the
number of potential donors. This was an advance
because many BX matches provided good increments
in the refractory patient. However, the predictive
power of this approach was poor. Poor responses were
frequent with BX matches and a surprising number of
good responses were seen with C and D matches. The
patient in the parable had a poor response to a
“phenotypic match” at the Kidd locus.
The study of Duquesnoy et al.16 can be criticized in
retrospect because no serologic assessment was
performed. They did not know if the patients had HLA
antibodies and, if they did,what the specificities of the
antibodies were. These determinations are always
performed prior to a RBC transfusion, as was suggested
by “Dr. Petz-Garratty.”
The poor predictive power of the CREG method
can be understood to some extent by examining the
results of serologic studies in these patients. For many
years, the standard serologic test for HLA antibodies has
been a lymphocytotoxicity (LCT) assay, the antihuman
globulin–augmented complement-dependent cyto-
toxicity test (AHG-CDC). In this assay, leukocytes from
50 to 100 donors with an appropriate heterogeneity of
HLA types are incubated in wells with the patient’s
serum and complement. LCT is assessed micro-
scopically. The presence of HLA antibody correlates
with poor response to randomly selected platelets17
and with improved response to HLA-selected
patients.18 On the other hand, if such antibodies are
not present, poor responses are infrequently improved
by HLA matching.18–20
In our laboratory, one half of patients referred for
matched platelets have no antibody.21 We discourage
matching in such patients except in the rare
circumstance that immunologic refractoriness is
mediated solely by antibodies to human platelet
antigens (HPAs). The results of the AHG-CDC assay
determine not only the presence or absence of
antibody, but also the breadth of immunization
expressed as the percent reactive antibody (PRA), the
percentage of wells in which lymphocytotoxicity is
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seen. Furthermore, by analyzing the positive wells, one
frequently can determine the specificities of the
antibodies. When we analyze results with the LCT
assay in refractory patients, the PRAs can range from 1
percent to 100 percent, so one can classify patients as
mildly (1–40% PRA), moderately (40–70% PRA), and
severely (PRA > 70%) immunized.
Furthermore, when the specificities are
determined, frequently one can identify intra-CREG
antibodies: antibodies against antigens within the
patient’s CREGs. With these facts in mind, one can
understand why the CREG method has a relatively poor
predictive capacity. When a BX match fails, there may
be intra-CREG antibody. When a C or D match
succeeds, the patient, although immunized, may have
no antibody against the antigens present on the
transfused platelets. There is a computer program
available to better predict successful BX and C and D
matches.22,23 It is known as “HLA Matchmaker.”
Furthermore, donor selection may be improved by
“HLA Matchmaker.” It is based upon the concept that
HLA molecules express their antigenic determinants as
amino acid triplets. These triplets are shared among
otherwise unrelated HLA molecules. Antigens whose
triplet complement is identical to ones present in the
patient are highly likely to provide compatible
products for an immunized patient. BX matches with
fewer triplet mismatches may be more likely to
succeed, as would triplet-identical C and D matches.
This concept awaits validation in a clinical study.
A quite different approach, crossmatching of donor
platelets with a patient’s serum, was introduced in
1988 and, later, in 1997.10,24 The most commonly used
method, at least in the United States, has been the solid
phase red cell adherence (SPRCA) assay, which is
available commercially as Capture-P from Immucor,
Inc. (Norcross, GA). The platelets of the potential
donor are layered in microtiter wells and the patient’s
serum is added.
The platelets are then washed and anti-IgG–coated
indicator RBCs are added. If there is antibody to the
platelets, the RBCs form a thin film in the well. If there
is no antibody, the RBCs puddle in a button on the
bottom of the well.
Many centers simply take platelets from inventory
and perform “blind” crossmatching, with no pre-
selection of the donors by identifying the antigens to
which the patient has formed antibodies. This stands in
contrast to RBC matching, in which cells are
deliberately chosen for crossmatching that lack the
antigens to which the patient has been sensitized.
The crossmatch method has the advantage of being
fast, once the patient’s serum is in hand. In addition, it
is a form of screening for the presence of antibody. In
our experience21 comparing the SPRCA to the AHG-
CDC assay, both tests detect antibody in 50 percent of
referred patients, while all crossmatches are compat-
ible in 30 percent. It is very rare for the SPRCA to be
entirely negative (compatible) when the AHG-CDC is
positive. Thus, if all crossmatches are compatible, it is
very unlikely that the patient is refractory for
immunologic reasons. On the other hand, 20 percent
of these cases are SPRCA positive and AHG-CDC
negative. The majority of such cases are seen in group
O patients who have positive reactions to donors who
are group A and/or B. In this situation, the positive
crossmatch would be considered falsely positive since
the platelets may be an excellent HLA match.
Recent results from Gelb and Leavitt24 in 76
potentially immunized patients indicated a mean CCI of
1800 for randomly selected products and 9800 for
crossmatch-compatible products. However, there were
no compatible products for ten patients. Another mode
of support based on HLA matching might have helped
these ten patients. Furthermore, in the other 66
patients, the mean percentage of screened units that
were compatible was 69 percent (range: 24–100%),
suggesting that these patients were only mildly or
moderately immunized. Overall, 59 percent of
crossmatch-compatible products produced CCIs greater
than 7500. On the other hand, 41 percent did not.
Crossmatching is an excellent way to begin support
when a patient needs a product urgently, if appropriate
technical staff are available (i.e., perhaps not on nights
or weekends). It provides a quick answer to the
question of whether or not the patient is alloimmunized.
In our experience, it is generally satisfactory for mild and
moderate degrees of alloimmunization but less helpful
for the severely immunized. Furthermore, it may find a
very good HLA match incompatible because of ABO
antibodies in the patient. In our experience21 with
highly immunized patients, the majority of crossmatch-
compatible products are not successful unless the
degree of HLA compatibility is high.
A final approach was suggested by Dr. Peter Petz-
Garratty in the parable. Why not examine the patient’s
serum for antibodies and determine their antigenic
specificities? Then, provide antigen-negative products,
perhaps with a final check by crossmatching. In fact,
this approach was evaluated by Petz and Garratty et
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al.25 in a large number of alloimmunized patients. They
called it the antibody specificity prediction (ASP)
method. The specificities of the patient’s antibodies
were determined with the AHG-CDC method and
antigen-negative platelets from an HLA-typed donor
pool were selected for transfusion.This approach was
compared to “blind” crossmatching. The increments
were better with the ASP method, although not
statistically so since there was a large range around the
means for both methods. The authors also found that a
perfect A or BU match produced the best result.
We studied the PRA of patients over time, up to a
maximum of 16 months. Our results were similar to
those of Lee and Schiffer.26 PRAs tend to remain
constant over time, even as the patients continue to be
transfused. On the other hand, approximately 25
percent of immunized patients may lose their
antibodies over a period of months, a phenomenon
that we do not understand. In practice, this means that
one can perform an AHG-CDC assay once monthly to
monitor the patient’s status without concern for major
changes during the period.
A great advantage of the ASP method is that it
increases the number of potential donors. Further, if
one has identified the specificities of the patient’s
antibodies, one can distribute compatible products
from inventory at any time without the need for
testing. Our approach is outlined in Table 1.
It is clear that what Petz and Garratty et al.25 are
suggesting brings us to a method very similar to what
we do with RBCs. We are using more complex methods
but their cost is less than that of a failed matched-
platelet product. With current methods, frequent failed
platelet transfusions are accepted routinely. We would
not tolerate this with RBCs, since morbidity from an
incompatible RBC transfusion can be severe. However,
there is morbidity from a failed platelet transfusion: a
continuation of the patient’s bleeding risk.
In addition, a new generation of technologies
developed and used for organ transplantation can also
be used for the platelet-refractory patient. These are
discussed in detail in the next section. Briefly, new
techniques for determining the specificity of
antibodies take advantage of the ability to use isolated,
single HLA molecules in ELISA or flow cytometric–
based assays. This is in contrast to the AHG-CDC assay,
in which two to four antigens are expressed on each
target lymphocyte.
In addition, there are simple ELISA methods in
which the target is a wide variety of HLA antigens. One
could use these methods to screen patients for the
presence of HLA antibodies, perhaps every 2 to 4
weeks. With this approach, one can be proactive and
begin matching earlier. We could abandon the practice
of forcing patients to “earn” their matched products by
experiencing several therapeutic failures.
Platelet Matching: New Technology for the
Future
For solid organ transplantation, the detection of
circulating anti-HLA antibodies in allograft recipients
correlates not only with hyperacute, acute, accelerated,
and chronic graft rejection,27–29 but also with reduced
graft function and graft failure. Over the past 40 years,
a plethora of papers has been published, discussing the
merits of various antibody detection methodologies in
relation to the clinical outcomes of solid organ
transplants. In contrast, very little can be found in the
literature relating these methods to platelet transfusion
outcome. This may partly be due to the difficulty of
such research due to the confounding effect of variables
such as storage-related changes in platelet viability,
concurrent recipient nonimmunologic plate-let
destruction, and the difficulties of demonstrating
clinically significant changes in outcome in the context
of prophylactic platelet use. This meager literature is
further confused by the use of less sensitive “gold
standard”assays (unenhanced lymphocytotoxicity tests)
for antibody screening in many comparative studies.30
The objective of this portion of the review is to
discuss different testing methodologies currently in use
for the detection of anti-HLA antibodies as they relate
to platelet transfusion. We will also outline what we
Table 1 . Suggested patient management approach
A. Patient Refer ral:
1. Begin support from inventory by:
a. classic CREG method16 using patient’s HLA type
b. crossmatching of random units by SPRCA24
2. Particularly if using (a), strongly suggest HLA antibody screen
3. Urge clinicians to provide CCIs
B. If:
1. No HLA antibody is demonstrated, return to randomly selected
products; consider testing for HPA antibody, especially if concomitant
nonimmunologic platelet destruction is unlikely
2. Only ABO antibody is demonstrated, use platelets from ABO-identical
or group O donors
3. HLA antibody is demonstrated but PRA < 70%, support from
inventory using crossmatching24 or antigen-negative platelets selected
by antibody specificity prediction method25
C.Monitor CCIs to judge response
D. If PRA > 70% and/or CCIs ar e poor :
1. Crossmatch antigen-negative platelets24,25
2. Establish transfusion schedule and selectively recruit A, BU, or other
very close matches
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believe to be the optimal approach to characterizing
the HLA antibody profile of highly sensitized platelet-
refractory patients.
HLA Class I antigens are expressed on all nucleated
cells, including platelets. HLA Class I antibodies are
relevant not only to solid organ and tissue trans-
plantation, but also to WBC and platelet transfusion.
Class II antigens are expressed on B cells, monocytes,
macrophages,dendritic cells, and activatedT cells. HLA
Class II antibodies are therefore unimportant in the
context of platelet transfusion.
Within the relevant Class I HLA-A and HLA-B
families (HLA-C being present on the platelet surface in
a density too low to be clinically important), there are
several CREGs, which express multiple public
epitopes. These public epitopes are common antigenic
determinants shared by different HLA antigens. HLA-B
locus antigens have two mutually exclusive public
epitopes, Bw4 and Bw6, as well as a number of others
defining the CREGs, such as 5C, 7C, 22C, 27C, 8C, 12C,
and 21C. Private epitopes refer to antigenic
determinants specific for an individual antigen. In
addition to “foreign” CREGs, patients can occasionally
make antibodies to antigens within their own CREGs,
either to private epitopes or to different public
epitopes within a CREG.31 The CREG antibody profile
remains remarkably constant over time in patients.31,32
Monthly fluctuations in PRA, if not due to new
transfusion events or changes in assay technique or
panel composition, usually reflect the waxing and
waning of detectable specificities within the same
CREG, or they can reflect the increasing strength or
number of reactivities within the same CREG cluster.30
In the transfusion setting, we have observed that
greater than 50 percent of sera screened by flow
cytometric methods contained both IgM and IgG
antibodies.33 These are mostly directed against public
epitopes or high-frequency private epitopes present in
transfused units. Additionally, some antibodies arise
from an anamnestic response from prior sensitization
to paternal antigens during pregnancy.34,35
Antibody screening provides information regarding
the presence or absence of HLA antibodies, the PRA
against HLA alloantigens, antibody specificities, the
immunoglobulin isotypes produced, and even antibody
titers. This information may in turn be used to predict
products likely to provide successful patient platelet
concentration increments.21,25 The ideal screening
method should be sensitive enough to detect the
lowest level of clinically relevant IgM and/or IgG
antibodies.
The original NIH two-stage complement-
dependent cytotoxicity assay (CDC)36 used for HLA
phenotyping is illustrated in Figure 1,30 which depicts
the two steps of the basic CDC method with
alternative steps (indicated by asterisks) included to
illustrate (1) extended incubation to allow low
avidity/affinity antibodies to bind cellular antigens; (2)
a wash step to remove unbound serum and minimize
“anticomplement factors,” which may inhibit or
weaken complement activity (Amos modified
technique)37; and (3) goat AHG-CDC, which overrides
inefficient C1q binding by single IgG molecules.38,39
Many of the anti-public or “CREG” antibodies are not
detectable by the standard CDC method due to
inefficient complement activation by HLA antibodies.
This is termed the cytotoxic-negative, adsorption-
positive phenomenon (CYNAP).40 The AHG-CDC
method is the most sensitive of the four complement-
dependent cytotoxicity tests. In some laboratories, the
sensitivity of the AHG-CDC is comparable to the
multiple-antigen-panel ELISA-based technique.
The major advantage of complement-dependent
assays is the ability to detect both IgG and IgM
antibodies. While IgM anti-HLA antibodies do not play a
role in solid organ transplantation, this may not be the
case in platelet transfusions. The disadvantages of
complement-dependent assays include the detection of
not only HLA-specific antibodies but also nonspecific
specificities or autoantibodies. The latter can be
Fig. 1 . The original NIH two-stage complement-dependent cytotoxicity
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eliminated by heating the serum at 63°C for 10 minutes,
treating the serum with DTT, or performing an
autocrossmatch in parallel. CDC-determined PRAs may
fluctuate due to changes in panel cell composition or
poor viability of frozen cells. Without prior adsorption,
sera obtained from patients receiving OKT3 or anti-T cell
immunoglobulins cannot be tested by CDC methods.
There are two forms of solid phase–based methods:
the ELISA41,42 and flow cytometric assays.43–45 These
methods employ purified soluble HLA antigens affixed
to solid phase matrices (plastic trays for ELISA or beads
for flow cytometry) as targets for the binding of HLA
antibodies instead of the live cells employed in CDC
assays.
The advantages of solid phase–based methods are
the ability to distinguish between IgG and IgM
isotypes, better detection of HLA-specific antibodies,
objective end-result determination by instrument
optical density readings, the lack of assay interference
by OKT3 treatment, and faster turnaround time.
Currently, ELISA assays are available in two or three
formats. The first is the screening test for the presence
or absence of HLA antibodies. A pool of HLA antigens
is affixed to a single well for this purpose. Positive sera
are further defined using a panel of HLA antigens
purified from EBV cell lines or platelets to allow the
determination of PRA and antibody specificity. The
sensitivity and specificity of ELISA using heterozygous
antigen panels (i.e., each well coated with multiple
antigens) is comparable to that of the AHG-CDC
method. A third type of ELISA tray is the high-definition
(HD) or single-antigen tray. Each well in the tray is
coated with a single HLA Class I–soluble antigen
derived from recombinant DNA technology.46 This
high-definition antigen panel provides the ideal tool to
characterize antibody specificities contained in high-
PRA sera. Both the sensitivity and the specificity of
screening sera using high-definition ELISA trays are
increased when compared with the AHG-CDC
method.47 In general, the ELISA method is not sensitive
for the detection of IgM HLA antibodies.
Similar to the variety of ELISA methods, there are
also three kinds of flow beads available: polyspecific
beads, useful as a screening tool; beads coated with
heterozygous soluble Class I antigens to determine
PRA; and antibody specificity or high-definition flow
beads. Currently the high definition beads consist of
34 individual recombinant A locus antigens, 57 B locus
antigens, and 19 C locus antigens.
Recently, another flow cytometric platform was
developed, based upon Luminex Microsphere (bead)
technology. This technology combines two of the most
powerful detection and identification tools, the
exquisite binding specificity between biotin and
streptavidin and the versatility of the flow cytometer.
By the precise blending of different fluorescent
intensities of the two dyes, 100 unique color codes are
created. When the colored beads are coated with
purified Class I antigens, they can be used for screening
and identification of HLA antibody specificities.
Although a number of large parallel studies between
standard and Luminex flow methods are still in
progress, data published thus far indicate that they are
likely to be comparable to each other.47
It is well established that flow cytometry methods
are more sensitive than AHG-CDC and ELISA. Better
clinical correlations are obtained using flow methods
not only for antibody screening but also for
transplantation crossmatches. Flow methods can
detect extremely low-level antibodies undetectable by
either AHG-CDC or ELISA methods.48–50
Considering reported sensitivities and specificities
together with our own comparison studies of AHG-
CDC versus ELISA or flow methods,33 our ranking of
preferred antibody elucidation methods for platelet-
refractory patients is: flow cytometry (HD panel) >
ELISA (HD panel) > AHG-CDC.
The optimal approach to characterizing the HLA
antibody profiles of highly sensitized patients, in our
opinion, is to HLA type potential platelet recipients and
to perform a thorough determination of the antibody
specificities using either ELISA or flow methods on
high-definition antigen or bead panels. Knowledge of
the recipient’s HLA type assists in analyzing the
antibody profiles. Patients can only produce HLA
antibodies against mismatched public and private
epitopes. Patients are less likely to be sensitized by
antigens belonging to their own CREG groups,although
intra-CREG antibody formation is not uncommon.
Screening high-PRA individuals using high
definition trays sometimes results in near-100 percent
panel reactivities. This is mostly due to the presence of
high-titer antibodies. We now use high initial optical
density readings (O.D. > 2.0) from the screening assay
for the presence of HLA antibodies as a guide to dilute
these high-titer PRA sera 1:10 or 1:20 for subsequent
screening on high-definition antigen or bead panels.
The few antigens to which these individuals are not
sensitized may be confirmed with compatible
lymphocyte crossmatches from products negative for
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the corresponding antigens.
Our ultimate goal is to rapidly identify individuals
with HLA Class I antibodies and attempt to provide so-
called antigen-negative platelet products, even to highly
sensitized patients, akin to the traditional approach
outlined above for RBC transfusions. While this approach
may be somewhat expensive compared with the current
practice of therapeutic trial and error, the savings
engendered by early identification of alloimmunization
and consequent avoidance of failed transfusion,
prolonged thrombocytopenia, and associated morbidity
and costs may be justified in the long run.
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